Deregulated Wnt/β-catenin signaling, often due to CTNNB1 and AXIN1 mutations, cooperates with other oncogenes to drive HCC and mediate resistance to therapies [7,9]. The gene discussed is CTNNB1; the disease is hepatocellular carcinoma.